News Articles and Montana BioScience Alliance Newsletters
Solo-Dex has announced an exclusive Product Distribution Agreement for Solo-Dex Fascile® suite of products with CH Trading Group LLC, an international import, export and trading company. The Agreement focuses on the MENA regional markets and extends the availability of Solo-Dex Fascile products beyond the U.S., Europe and Brazil to dozens of countries, including those that are part of the Gulf Cooperation Council, the African Union and the Organization of Islamic Cooperation.
The “MR” designation means that patients no longer need to interrupt their pain management to obtain MR imaging. In addition, patients no longer need to undergo repeat placement of a nerve block catheter following an MRI imaging. Solo-Dex green “MR” designation will improve patient satisfaction, reduce costs and drive efficiency in a hospital and in the ambulatory surgical center.
Fifty-eight high school graduates from across Montana have been selected for their effort and potential as the seventh class of Montana State University’s Hilleman Scholars Program, which is named after Maurice Hilleman, one of the state’s most influential, but least known, native sons.
Manually converting FASTQs to VCFs, importing these into VarSeq, and building projects from scratch is adequate when you have only a handful of cases per week. But as you start ramping up production, the key to your lab’s success quickly becomes how quickly and efficiently you can get to the reporting of your analysis. This blog will explain how you can automate the VCF and VarSeq Project generation process that requires only a few commands. This will expedite your path to analysis […]
Tonix Pharmaceuticals has received a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300 a recombinant enzyme that efficiently degrades and metabolizes cocaine. In 2021, more than 24,900 individuals in the U.S. died from drug overdose deaths involving cocaine.
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.